Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
The following paper looks promising since it focuses on MDx in light of pandemic related disruptions to the lab system. I did not pay up for the full text, so I can't speak to the specifics.www.sciencedirect.com/science/article... FL
Flatlander schreef op 30 maart 2021 14:21 :
The following paper looks promising since it focuses on MDx in light of pandemic related disruptions to the lab system. I did not pay up for the full text, so I can't speak to the specifics.
www.sciencedirect.com/science/article... FL
Good news, I hope they make a press release out of it ! ;-)
Flatlander schreef op 30 maart 2021 14:21 :
The following paper looks promising since it focuses on MDx in light of pandemic related disruptions to the lab system. I did not pay up for the full text, so I can't speak to the specifics.
www.sciencedirect.com/science/article... FL
Here’s the Discussion: Although NGS is the standard method in our lab whenever personalized mutation testing for cancer therapy is required, the COVID-19 pandemics hindered the routine usage of this technique in the last six months. Several delivery chain interruptions forced us to check alternative methods for initial therapy decision-making based on the mutational status of cancer patients whose number did not decrease during the time of the pandemics. An alternative method to rapidly test cancer patients that was not affected by delivery chain breaks was the IdyllaTM platform (6). Our comparisons show that the cartridges have an acceptable overall performance and represent an excellent alternative for rapid therapy decision, which in nearly all cases would have been possible even in the absence of the NGS result. While NGS is more sensitive the clinical meaning of NGS is not always clear as it detects also minor cell populations in a tumor thus maybe leading to a moderate or minor improvement during subsequent therapy. Thus, in times when delivery chains are interrupted even in industrialized countries, Idylla TM can be a rapid an available alternative to maintain relevant diagnostics of diseases other than COVID-19. A disadvantage, however, of IdyllaTM (Biocartis, Mechelen, Belgium) is that the console can only analyze a sample for one type of mutation at a time giving limited insight into the patient's tumor composition. If multiple mutations are to be tested then the corresponding cartridges will have to be present on hand. The tests can be run in parallel if multiple instruments are being used, or in sequence if only one instrument is available, however maybe creating a financial problem, as the multiple cartridges have to be on stock in concert with multiple instruments to run analyses in parallel. If however, an institute aims on fast and only partial results (as only specific mutations are relevant to determine the course of personalized treatment), IdyllaTM is the better choice as it gives the specific result in approximately 2 hours (7). However, the specificity and the PPV of all the different mutation cartridges tested were all at 100%. For all the mutation types tested, if no mutation was present, IdyllaTM was capable of correctly recognizing this with a specificity of 100%. With a PPV of 100%, one can be certain that if the IdyllaTM test detects a mutation, that this mutation is in fact present. Despite these advantages, the fact that some mutations are not fully resolved such as the BRAF 600 mutations, remains a limitation of the platform, as the correct molecular classification is crucial for the final therapy decisions, thus Idylla cannot replace the NGS but reduce the gap that results from delivery chain interruptions. For EGFR the sensitivity lies at 93.3%, meaning 6.7% of the people tested with the EGFR mutation will not be detected. The NPV however, is much lower at 66%, as only two of the three samples detected negative for EGFR mutation were actually negative. The overall concordance between NGS and IdyllaTM for this mutation testing is 91.6%. Yet in another study, comparing Idylla EGFR results and NGS, the concordance is much higher at 97.59% testing 449 samples (8). Using the NRAS-BRAF test, there was also a high concordance between all the samples. KRAS testing has the second highest sensitivity of the mutation types tested at 91%. The NPV is only 25%, which does not give an accurate depiction of the KRAS test, as the NPV would likely increase if a higher number of samples were tested. A further bias of the Idylla system is the lack of a distinct differentiation between BRAF 600 mutations, which could be crucial for therapy decisions. This has to be taken into account and it has to be recommended to apply further analyses in BRAF 600 mutated cases identified by IdyllaTM. Discordant results observed here in our study were in the majority a result of a missing in depth differentiation in the IdyllaTM system, i.e. the mutations detected were at the correct locations identified by NGS but the particular nucleic acid and/or amino acids exchange was not determined by the IdyllaTM system. In case of BRAF mutations, the IdyllaTM system contains solely mutations at position 600, while NGS also detects mutations outside this region, although the clinical meaning of these mutations is minor. A further mutation at position 61 of KRAS specimen 8 was likely missed by IdyllaTM due to a lack of sensitivity, either because the tumor specimen on the FFPE block was not sufficient or did not contained mutated allelic variants above the IdyllaTM threshold, maybe because of tumor heterogeneity. However, it is important to keep in mind that from a practical point of view the lack of more detailed information regarding the EGFR deletion mutations in the Idylla system would not have altered the therapy regimens, but from a pure scientific point of view must lead to the conclusion that the mutations were not determined fully correct. Anyway, as also in German round robin trials the Idylla method was accepted and the loss of detailed information on the mutations were not penalized as long as the correct treatment decision could be made, this fact was neglected in the subsequent calculation on sensitivity, specificity, and predictive values.
Pablo Thanks for the expanded discussion. This sentence pretty much encapsulates the take away: "Our comparisons show that the cartridges have an acceptable overall performance and represent an excellent alternative for rapid therapy decision, which in nearly all cases would have been possible even in the absence of the NGS result. " We all know that there are some limitation and that Idylla is not the platform to explore all mutations. Rather BCART has focused on ones that are actionable (have readily available treatment). The article's point about needing multiple cartridges should bot be a deal breaker since the cartridges have a year shelf life and can be stockpiled and used later. I assume that the point about the BRAF 600 and the EGFR mutation sensitivity is probably the reason that BCART has indicated that revamped cartridges and/or combination cartridges are in the works for next year. The concern here is the one that has always existed: in some cancers such as NSCLC there is often only a small amount of material available for testing. That is why the use of de-stained cytology smear samples may be important. Based on what I've read there continues to be a significant market for fast analysis of actionable targets but also for surveillance tracking of mutations during treatment. So what did we learn 1) Idylla has a useful role coming out of the pandemic by providing rapid actionable results thus alleviating some of the lab testing burden, 2) there is a need to revamp some of the assays to improve specific mutation sensitivity. My hope is that the management team now has a couple years at the helm under their belt, so hopefully they can implement changes and improvements that allow Idylla to evolve quicker. Thanks FL
PERSBERICHT: Persbericht Biocartis Group NV: Biocartis kondigt publicatie van 2020 jaarverslag aan FONDS KOERS VERSCHIL VERSCHIL % BEURS Biocartis NV 4,475 0,00 0,00 % Euronext Brussel PERSBERICHT: GEREGLEMENTEERDE INFORMATIE 1 april 2021, 07:00 CEST Biocartis kondigt publicatie van 2020 jaarverslag aan Mechelen, België, 1 april 2021 -- Biocartis Group NV (de 'Vennootschap' of 'Biocartis'), een innovatief bedrijf in de moleculaire diagnostiek (Euronext Brussels: BCART), kondigt vandaag de publicatie van zijn 2020 jaarverslag aan. Het 2020 jaarverslag biedt een overzicht van de cijfers en prestaties van Biocartis voor het boekjaar afgesloten op 31 december 2020. Het verslag is beschikbaar als PDF-bestand en kan vanaf nu www.globenewswire.com/Tracker?data=nc... hier worden gedownload vanop de website van de Vennootschap. --- EINDE ---
ImmunExpress and BCART should hear back from FDA soon on the December 2020 510K filing for Septicyte Repid. www.meddeviceonline.com/doc/how-long-... ,additional%20information%20(AI)%20requests. FL
I wish we did not have to wait for the Annual Report for Updates non the Geographic Rollout of Idylla. "Distributor markets22 – In 2020, several countries that are served through distributors were hit specifically hard by the pandemic, often compounded by a significant weakening of local currency versus the Euro. As a result, declining volumes in amongst others Latin-America, India, Pakistan and Turkey outweighed continued growth in other parts of the world. New market authorizations were obtained for the Idylla™ MSI Test in Colombia, Canada, Malaysia and Singapore,and for the Idylla™ EGFR Mutation Test in Argentina during H1 2020. End of October 2020, medical device registration certificates were issued for the Idylla™ platform and the Idylla™ EGFR Mutation Test by the Taiwan FDA. Post the reporting period, in February 2021, the Idylla™ platform, the Idylla™ BRAF Mutation Test (CE-IVD) and the Idylla™ EGFR Mutation Test (CE-IVD) completed registration in Russia, as such expanding the distribution network for Biocartis’ IVD medical devices. FL
What is missing to me are some forward looking statements for 2021. Couldn't find any. When would these come? Or did I miss them completely?
COVID-19 IMPACT EN 2021 VOORUITZICHTEN Het jaar 2021 zal opnieuw in het teken staan van de aanhoudende gevolgen van de pandemie. Het zicht op de timing van normalisering van de wereldwijde kankerzorg is beperkt. Het is evengoed moeilijk om op betrouwbare wijze te voorspellen hoe de verdere behoefte aan SARS-CoV-2 testing zal evolueren naarmate de vaccinatie in de loop van het jaar in de verschillende landen in een verschillend tempo vordert. Met een breed Idylla™ testmenu in oncologie en een aantrekkelijk Idylla™ pandemie response menu gelooft Biocartis niettemin dat het zijn groei kan versnellen en volgende doelstellingen kan bereiken: Commercieel cartridgevolume: Beoogde jaar-op-jaar groei van 40%-60% of commercieel cartridgevolume in de range van 320k-370k. Het plafond van de range zal enkel worden behaald ingeval van consistente sterke vraag naar de Idylla™ SARS-CoV-2 Test aan aantrekkelijke verkoopsprijzen doorheen 2021; Installed base: Beoogde nieuwe Idylla™ instrument plaatsingen tussen 300-350; Kaspositie: Beoogde kaspositie van tenminste EUR 50 miljoen op jaareinde, inclusief potentiële investeringen in het upgraden en uitbreiden van het infectieziekten testmenu.
I've said this before but I'm pretty certain that BCART PR downplays information that might garner the attention of competitors (geographic information breakdown, anticipated IVD registration/launch dates, etc.). We all know this field is hyper competitive. The last thing BCART wants is for a bigger, better funded competitor to come in and try to sell the lab, hospital, university, clinic, etc on their alternative MDx platform right before a new Idylla launch, For this reason I'm not dwelling on the financial metrics when most of the world is still in RUO authorization mode. That said the graph on pg 114 finally started to show some performance metrics starting to trend the right direction. The combination of the use registrations (MSI in the USA and Asian registrations) and the release of pent up oncology demand as the pandemic winds down could set the backdrop for a dynamic 2022. FL
Duidelijk dus over gelezen en/of gemist. Bedankt voor de info!
A potential reason we are not hearing about the Idylla EUA approval from the FDA. Other automated PCR tests (GeneExpert by Cepheid) are having difficulty detecting variants. FLwww.medpagetoday.com/special-reports/...
Other players using DNA-screening, interesting readwww.tijd.be/ondernemen/farma-biotech/...
and again down down down :-( What on earth could get some spark in this shareprice ...
Misschien een goedkeuring van FDA of een kapitaalinjectie van een Ursula krijgt ze ineens een zitje in de raad van bestuur. Dan moet boer charel zijn gat nie heffen.
tomtesteron schreef op 9 april 2021 16:55 :
and again down down down :-(
What on earth could get some spark in this shareprice ...
Overtreffende resultaten Q1 2021 rapport op 22 April
@ Goededag,het is maar de vraag of"overtreffende"resultaten er nog iets aan toe doet.Zo snel mogelijk zekerheid over de financiering van de komende jaren staat bij mij op 1 om de huidige manisch depressieve koersontwikkeling een halt toe te roepen.
CGCDLR schreef op 10 april 2021 16:53 :
@ Goededag,het is maar de vraag of"overtreffende"resultaten er nog iets aan toe doet.Zo snel mogelijk zekerheid over de financiering van de komende jaren staat bij mij op 1 om de huidige manisch depressieve koersontwikkeling een halt toe te roepen.
CGCDLR You know my argument. It doesn't matter much until Idylla is allowed to be marketed for diagnostic use. But in markets where products already have IVD approval, the uptake is or will be driven by two things: 1) the buildout of the offerings menu. The more the machine can analyze the more the incentive to buy into the ecosystem; 2)Technical papers validating the product are in a sense a testimonial - this is a very strong mechanism for sales. This is especially true in cases where the papers identify or flow charts how Idylla can be incorporated into a labs day to day work flow to improve turnaround time, save money and/or make money for the lab. As always, there are catalysts on the horizon but ultimately BCART will have to demonstrate that they are clearly on the road to profitability. FL
Novacyt (ALNOV.PA) got pounded down 38% yesterday, they loss a DHSC contract that accounted for 50% of sales. It is apparent that the contract loss was due to refusal to further negotiate a reduction in pricing for the government contract. This is why you hate to put in writing (as Novacyt did) that your products have an 80% margin. I sold out of a portion of my position in the Fall, so that I recouped all my original investment and am playing with the houses money. That said. Novacyt should have around 200 million in the bank so the company itself is now being valued at bargain basement prices. I think the pandemic testing will persist for a couple years and Novacyt will find a market for their products in foreign markets and in the private sector. They are a leader in PCR analysis of variants. They are extremely quick to win new product approvals, so I think the market is now undervaluing the company and its IP. Given what Hologic is spending for a Finnish PCR maker, I think it s worth acquiring shares of Novacyt again. However, this does point out an advantage to the BCART business model. Idylla sales are well diversified and are not concentrated in a single entity, www.bizjournals.com/boston/news/2021/... FL
FL,dank u wel,ik heb veel appreciate voor uw altijd heldere, positieve bijdrage.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee